Ting Zhou, PhD

Director, Stem Cell Research Facility
Ting Zhou, phD

Office Phone



Ph.D. Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences

Dr. Zhou is an experienced stem cell biologist with great passion to develop state-of-the-art human pluripotent stem cell (hPSC) technologies and apply them to drug screening and disease investigation. Dr. Zhou was a pioneer in establishing a protocol for using human urinary cells as a source to generate iPSCs in a noninvasive manner. Utilizing this protocol, she developed a panel of iPSC models for studying premature aging and cardiovascular diseases. She has also combined the hPSC technology with chemical screens and the latest genome editing technologies such as prime editing, base editing, and CRIPSR/Cas9 based knock-out and knock-in in hPSCs for her own research and collaboration projects. 

Looking forward, Dr. Zhou will continue to use her expertise to contribute to the development of the stem cell field, and she welcomes collaboration with investigators of all levels from MSK, the Tri-institutes and other institutions. 


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ting Zhou discloses the following relationships and financial interests:

  • Cell Press
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures